Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Oct 20 - Oct 25
Retatrutide (2026) Semaglutide Mechanism: GLP-1 receptor agonist FDA Status: Approved for diabetes and weight management Expected Weight Loss: 1520% body weight Administration: Weekly injection Onset: Appetite changes within first few weeks Cost: Membership pricing at Better Med Spa see plans Tirzepatide Mechanism: Dual GIP + GLP-1 receptor agonist FDA Status: Approved for diabetes and weight management Expected Weight Loss: Up to 22% body weight Administration: Weekly injection Onset: Often faster appetite suppression Cost: Membership pricing at Better Med Spa see plans Retatrutide Mechanism: Triple agonist (GLP-1 + GIP + Glucagon) FDA Status: NOT approved investigational only Expected Weight Loss: Early data suggests very potent effects (up to 24% in trials) Administration: Weekly injection (investigational protocols) Onset: Under investigation Cost: Not yet available What Are Semaglutide, Tirzepatide, and Retatrutide
They are potent biologic therapeutics with 35 listed adverse side effects, and caution warnings for people with existing conditions such as pancreatitis, suicide ideation and thyroid cancer
The monoamine hypothesis of depression has been the main pathophysiology and drug therapy target of depression over the past few decades, but the current monoamine theory has serious limitations ( The relationship of multiple ACs in vivo and psychiatric disorders such as depression has yet to be further investigated
Apple Newsroom
US$ 24.91
US$ 25.85
US$ 28.04
